2024
Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
Jacobs J, Booth G, Raza S, Clark L, Fasano R, Gavriilaki E, Abels E, Binns T, Duque M, McQuilten Z, Mingot‐Castellano M, Savani B, Sharma D, Tran M, Tormey C, Moise K, Bloch E, Adkins B. Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions. American Journal Of Hematology 2024, 99: 2351-2366. PMID: 39324647, PMCID: PMC11560617, DOI: 10.1002/ajh.27487.Peer-Reviewed Original ResearchHematological conditionsFcRn inhibitorsClinical trialsStandardized treatment algorithmClinical trial dataNeonatal Fc receptorIn vivo studiesImmune-mediatedHematological disordersTreatment algorithmTransports IgGAdverse eventsImmunomodulatory/immunosuppressive therapiesIgG levelsPatient populationProtective IgGFc receptorsTherapeutic strategiesMucosal surfacesRheumatologic conditionsIgG antibodiesImmunoglobulin isotypesTrial dataIgGFcRn
2023
Hemolytic disease of the fetus and newborn mediated by anti-Dia in a U.S. hospital
Jacobs J, Abels E, Binns T, Tormey C, Sostin N. Hemolytic disease of the fetus and newborn mediated by anti-Dia in a U.S. hospital. Immunohematology 2023, 39: 32-34. PMID: 37017601, DOI: 10.21307/immunohematology-2023-006.Peer-Reviewed Case Reports and Technical NotesConceptsHemolytic diseaseCases of HDFNU.S. hospitalsHemolytic transfusion reactionsDirect antiglobulin testNeonatal bilirubin levelsSouth American descentAntibody detection testsLow-prevalence antigensU.S. patient populationNear universal absenceHDFN casesBilirubin levelsPatient populationTransfusion reactionsAntiglobulin testUnexpected causeHispanic ethnicityBlood group systemAntigenAntibodiesHDFNHospitalFetusesDisease